Canada markets closed

Medtronic plc (MDT)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
94.82+0.78 (+0.83%)
At close: 04:00PM EDT
94.82 0.00 (0.00%)
After hours: 04:51PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • J
    JonK
    MDT has huge backorder issues involving key products. Failure to supply, will cause many contracts currently in place to become null and void. Hospitals are actively seeking new suppliers for these key products (Ligasure for example). How long will this last and even more importantly, how long will it take to regain that lost business? Proceed with caution IMO, this is an open door for competitors to get footholds in places MDT has been dominant.
  • R
    Rex
    Waiting for a 3.5% yield to buy in
  • S
    Sunshine Design
    Still adding!
  • m
    marek
    This stock is now back where it was 5 years ago and will continue sinking. This company is in the middle of its 4th huge layoff of key personnel in clinical and safety. While this will fluff the earnings slightly, be ready for more recalls and FDA rejections. The company has gotten too big in terms of product and too thin on personnel that can manage.
  • B
    Bill mddb
    The drag on MDT earnings has been primarily do to supply lines in China and sales in China have been way down - sounds like some good news from China:

    Retail car sales in China continued to trend upward amid a post-lockdown recovery, according to the China Passenger Car Association (CPCA).

    The agency reported that sales leapt 28% in the week of June 20 to June 26 from the same period in the prior year, with passenger vehicle sales rising to 487K units, up 33% from the prior year and increasing 17% from the prior month. For the month of June observed thus far, passenger car sales in the region reached 1.42M units, a year-on-year increase of 27%.

    Despite the rise in sales, many of the major automakers that are either based in China or maintain strong market share in the country fell on Wednesday.
  • P
    Pat
    they should of bought isrg
  • B
    Bill mddb
    I just added 50 shares, not much compared to my pile. I have cash to eventually invest so I couldn't resist given the long term prospects and current yield. I would follow it done some at the same 50 shares as I think about it today.
  • B
    Bill mddb
    MDT shares are going thru a market winter phase. They did say that inflation especially increased freight costs will be rolling thru the income statement thru the first two fiscal quarters 5/1/22 - 7/31 and 8/1/22 - 10/31/22. So that will counterbalance increased revenues as COGS will reduce gross margins. The stock should be helped by good product news especially FDA approval of the Renal Denervation procedures. We could see a sideways drift. I own quite a bit so I would only add on some big market selloffs if they come. Below is a quote from the CFO on the last earnings call, MDT's cash flows have been strong so they are back to buying back stock...

    This past year, we paid $3.4 billion in dividends and we're supplementing that through opportunistic share repurchase, particularly in periods where we see share price dislocation. In fact, we repurchased over $2.5 billion of our stock in fiscal '22, including $1.4 billion in the fourth quarter.
  • B
    Bill mddb
    Not a lot of volume, up on a dearth of sellers. That's okay given the bluster about Taiwan. I can see Xi's point about sanctions hurting everyone's supply lines.
  • B
    Bryce R
    52 week low; annual dividend coming in a few weeks. Buy buy buy
  • S
    Sunshine Design
    Adding!
  • B
    Bill mddb
    I don't see any material issues with MDT. The high end of their estimate for FY 23 $5.65 vs the prior analyst composite $5.66. I think it was expected that MDT would exceed the $5.66. I also think that they should exceed the $5.65 because they want to be able to come in over $5.65. They had been on a trend of coming in higher than each Q target. They hired Mike Weinstein who retired from JP Morgan in 2018 as strategy VP and better relations with analysts. They will want to get back to doing that. But some edge is gone. I think FDA approval of their renal denervation will be a catalyst to move it up 10%. So I'm looking to add more but waiting until it plays out tomorrow.
  • J
    Javier Isaac
    Solid company with good fundamentals just lagging due to temporary circumpstances (covid and supply chain)
  • B
    Bill mddb
    The current composite analyst estimate for this year ending 4/28/23 is $5.57. So trading at $96.50 as I type is 17.3x. MDT's high end estimate is $5.65. The analyst composite for FY 24 ending 4/28/24 is $6.03. So the forward p/e for $6.03 is 16x.
  • E
    EngrJohn
    I sold all my shares of MDT and purchased ZTS which is another health stock. I waited too long to sell MDT. I have a better chance to make money with ZTS.
  • B
    Bill mddb
    Big volume day. I'm watching and waiting for follow up comments or rating changes from analysts. I'm not sure how to spell his name but Anji Kumar has been a long term supporter of MDT and he was surprised by the $350 mil revenue miss - so MDT may get pounded down today and next week. But MDT is not alone, if you look at medical devices EW & SKY have also lost quite a bit of market position for similar reasons.
  • B
    Bill mddb
    A 3% yield on $2.77 is at $92.30. It could happen. In the last 7 days the analyst composite est. for Q1 went from $1.37 to $1.12 and the FY 23 est. went from $5.81 to $5.57. That's a material drop for Q1 ended 7/31/22. That's the backdrop for the weakness. MDT said in the conference call that Q1 and probably Q2 will see revenue up but margins down due to price hikes in their supply chains. MDT sells forward so it's being caught by higher freight costs in Q1 & Q2 that it can't pass on to its consumers. But they also said the back half should be stronger.
  • B
    Bill mddb
    Needham has downgraded Medtronic (NYSE:MDT) from buy to hold following the medical device company fiscal 2022 Q4 results that missed on the top and bottom lines.
    Analyst Mike Matson said that Medtronic "seems to have returned to its old pattern of poor execution and inconsistent results" adding that its peers are handling a challenging environment more successfully.
    He also views pipeline challenges (renal denervation and robotics) and receiving a U.S. FDA warning letter in December 2021 following an inspection of the company's Northridge, Calif., facility, the home of its diabetes business, as obstacles for the company.
    Seeking Alpha contributor Edmund Ingham wrote that despite the diabetes woes, Medtronic (MDT) is still investible due to its neuro, cardio, and medical surgical franchises.
  • S
    Steve
    Buy orders in at 95 and 90